News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eddingpharm (Cayman) Inc. Announces Closing of $24 Million Series B Funding


9/17/2010 7:11:06 AM

WANCHAI, Hong Kong, Sept. 17 /PRNewswire/ -- Eddingpharm (Cayman) Inc., a leading specialty pharmaceutical marketing company focused on the China market, today announced the closing of a US$24 million Series B financing, co-led by OrbiMed Advisors Caduceus Asia Partners Fund and Domain Associates. Sequoia Capital China Growth Fund also participated in the financing. The financing will be used primarily for in-licensing of drugs from suppliers across the globe and co-development of new prescription drugs for sale in China, as well as to seek potential M&A opportunities. William Blair & Company, LLC acted as placement agent for the transaction.

Read at Yahoo Finance
Read at PR Newswire
Read at The Business Journals
Read at PharmaLive
Read at ChinaBio Today

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES